Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.
Eligibility Criteria
Inclusion Criteria: 1. Patients' age is ≥18 y 2. Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging or computed tomography)-that is not explained solely by loading conditions) 3. Non-obstructed left ventricular outflow obstruction with peak gradients \<30mmHg 4. Concomitant with persistent atrial fibrillation (7 days\<sustained episode lasting\<3 years) with drug-refractory symptoms. 5. Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation. Exclusion Criteria: 1. Patients with left atrial size \>60 mm (2-dimensional echocardiography, parasternal long-axis view) 2. Contraindicated to systemic anticoagulation 3. Left ventricular ejection fraction ≤40% 4. Concomitant with left atrium or